Stable Growth at Analytik Jena after Nine Months
(Thomson Reuters ONE) -
Analytik Jena AG / Stable Growth at Analytik Jena after Nine Months processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
- Sales within range of forecasts with 10.2 % increase
- Operating earnings below expectations
- Dividend payment remains goal for the financial year
Jena, August 12, 2010 - With sales of EUR 59.6 m, Analytik Jena AG (Frankfurt
DE0005213508, Prime Standard: AJA) has achieved an important milestone towards
being able to close the current financial year with record sales once again.
This was announced today by the analytical measuring technology manufacturer at
the presentation of its nine-month figures.
Sales and earnings
Analytik Jena generated consolidated sales of EUR 59.6 m (previous year EUR
54.1 m) in the first nine months of financial year 2009/2010, equivalent to a
year-on-year increase of 10.2 %. Operating earnings (EBIT) amount to EUR 3.2 m
(previous year EUR 4.9 m), a decline of 33.5 % as against the previous year. The
EBIT margin decreased significantly in the reporting period, ending it at 5.4 %
(previous year 9.0 %). Analytik Jena posted a net profit of EUR 2.5 m,
corresponding to earnings per share of EUR 0.47 (previous year EUR 0.55).
"With its nine-month figures, the Company is continuing its overall successful
business development. In addition to new record sales, we also want to exceed
the previous year in terms of earnings per share", said Klaus Berka, Chairman of
the Executive Board of Analytik Jena AG. "The causes of our below-expectations
result after nine months, and of the adjusted key figures for the year
2009/2010 as a whole, are mainly temporary effects which occurred across all
business units", continued Berka.
According to the Company, this is attributable to the persistent disappointing
sales in the Optics segment, where the anticipated recovery has not yet
occurred. Operating earnings also include one-off costs arising from combination
of the two subsidiaries Analytik Jena Japan Co. Ltd. and CyBio Japan Co. Ltd.,
which is being liquidated, in the amount of approximately EUR 0.3 m. Write-downs
totaling around EUR 0.6 m in relation to the purchase price allocation as part
of the acquisition of Biometra and CyBio must also be taken into account. The
EUR 1.2 m decrease in sales in Analytical Instrumentation as against the
previous year also reduced operating earnings.
In the core business of Analytical Instrumentation, Analytik Jena again saw a
stable sales development, generating sales of EUR 35.9 m (previous year EUR
37.1 m). However, the Company is still below its figures for the previous year.
As at the end of June, Analytik Jena managed to exceed the previous year's level
of incoming orders in Analytical Instrumentation for the first time in the
financial year. In view of the two major orders gained in the prior-year period
with a volume of approximately EUR 3.5 m, this can be considered an excellent
development. In the current fourth quarter, the Company expects to be able to
slightly exceed the previous year's annual sales in this division.
The growth segment of Life Science also continued its positive sales development
with strong growth rates. Here the Group generated sales of EUR 20.3 m (previous
year EUR 12.1 m) after nine months, equivalent to a 67.5 % increase. It should
be noted that the subsidiaries Biometra GmbH and CyBio AG were not yet fully
consolidated in the equivalent period of the previous year. Overall, this
division is currently still going through a phase dominated by research and
development as well as structuring of sales.
In the Optics division, Analytik Jena posted profitable sales of EUR 3.4 m
(previous year EUR 4.9 m) in the reporting period, 29.9 % lower than in the
previous year.
Balance sheet and cash flow
The Group's total assets rose as of the reporting date June 30, 2010, amounting
to EUR 79.7 m as compared to EUR 75.5 m as of September 30, 2009. Equity
increased to EUR 40.2 m (September 30, 2009: EUR 38.4 m), equal to an equity
ratio of 50.4 %. The Group's cash and cash equivalents amounted to EUR 7.2 m as
of the end of the reporting period, compared to EUR 10.4 m as of September
30, 2009.
Outlook
For financial year 2009/2010, the Analytik Jena Group anticipates earnings
before interest and taxes (EBIT) of around EUR 5.0 m and earnings per share
(EPS) of approximately EUR 0.60 with revenue amounting to roughly EUR 80.0 m. In
the fourth quarter, Analytik Jena will focus on improving earnings on the basis
of comparatively higher sales. In Analytical Instrumentation, the Company
expects the current remaining decline in sales to be cancelled out or exceeded.
In the coming quarter, the challenge in the high-growth Life Science segment
will be to continue the establishment of sales structures in the two key markets
of Japan and China, which was initiated at the start of the year, in order to
generate significant sales in the coming financial year. In the Optics division,
a slight recovery of the market is anticipated towards the end of the year
following a very weak start into the financial year. This recovery is also
expected to be reflected in increasing sales.
"We expect our growth path to be continued in our operating business, after the
current stabilization phase and we anticipate that we will be able to close
financial year 2009/2010 successfully and with record sales despite slightly
adjusted results", emphasizes Berka.
The detailed financial report is available at
http://berichte.analytik-jena.de/9-MonthReport_0910.pdf
Contact: Dana Schmidt, Media & Investor Relations
Phone: +49 36 41 77-92 81, Fax: +49 36 41 77-99 88
ir(at)analytik-jena.com, www.analytik-jena.com
[HUG#1437406]
--- End of Message ---
Analytik Jena AG
Konrad-Zuse-Straße 1 Jena Germany
WKN: 521350 ;ISIN: DE0005213508;Index:Prime All Share;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Analytik Jena AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 12.08.2010 - 08:09 Uhr
Sprache: Deutsch
News-ID 39477
Anzahl Zeichen: 0
contact information:
Town:
Jena
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 261 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Stable Growth at Analytik Jena after Nine Months"
steht unter der journalistisch-redaktionellen Verantwortung von
Analytik Jena AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
